Department of Otorhinolaryngology-Head and Neck Surgery, Chung-Ang University College of Medicine, 102 Heukseok-ro, Dongjak-gu, Seoul, 06973, Republic of Korea.
Department of Otorhinolaryngology, Seoul National University Hospital, Seoul national University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea.
Sci Rep. 2016 Dec 7;6:37153. doi: 10.1038/srep37153.
We developed a protocol of noninvasive prenatal testing (NIPT), employing a higher-resolution picodroplet digital PCR, to detect genetic imbalance in maternal plasma DNA (mpDNA) caused by cell-free fetal DNA (cffDNA). In the present study, this approach was applied to four families with autosomal recessive (AR) congenital sensorineural hearing loss. First, a fraction of the fetal DNA in mpDNA was calculated. Then, we made artificial DNA mixtures (positive and negative controls) to simulate mpDNA containing the fraction of cffDNA with or without mutations. Next, a fraction of mutant cluster signals over the total signals was measured from mpDNA, positive controls, and negative controls. We determined whether fetal DNA carried any paternal or maternal mutations by calculating and comparing the sum of the log-likelihood of the study samples. Of the four families, we made a successful prediction of the complete fetal genotype in two cases where a distinct cluster was identified for each genotype and the fraction of cffDNA in mpDNA was at least 6.4%. Genotyping of only paternal mutation was possible in one of the other two families. This is the first NIPT protocol potentially applicable to any AR monogenic disease with various genotypes, including point mutations.
我们开发了一种非侵入性产前检测(NIPT)方案,采用更高分辨率的皮升级液滴数字 PCR 技术,检测由游离胎儿 DNA(cffDNA)引起的母体血浆 DNA(mpDNA)中的遗传不平衡。在本研究中,该方法应用于四个常染色体隐性(AR)先天性感觉神经性听力损失的家庭。首先,计算了 mpDNA 中胎儿 DNA 的一部分。然后,我们制作了人工 DNA 混合物(阳性和阴性对照),以模拟包含突变或不包含突变的 cffDNA 分数的 mpDNA。接下来,从 mpDNA、阳性对照和阴性对照中测量突变簇信号占总信号的分数。通过计算和比较研究样本的对数似然之和,我们确定胎儿 DNA 是否携带任何父本或母本突变。在四个家庭中,有两个家庭成功地预测了完全的胎儿基因型,其中每个基因型都有一个明显的簇,并且 mpDNA 中的 cffDNA 分数至少为 6.4%。在另外两个家庭中的一个家庭中,可以对仅父本突变进行基因分型。这是第一个潜在适用于任何具有各种基因型的 AR 单基因疾病的 NIPT 方案,包括点突变。